WEBULL
WebtradeDownload

C-MER Medical Holdings (SEHK:3309) Stock Still Cheap After Profit Return

Simply Wall St · 3d ago

The market has been cool on C-MER Medical Holdings, with the stock down about 19% over the past three months and closing today at HK$0.845. Yet the latest half year numbers tell a different story. The company stayed profitable in H1 2026, with basic earnings per share of HK$0.0421 on revenue of HK$1,024.4m, and now carries a trailing P/E of 10x compared with higher industry and peer averages. The headline is simple: profitability has taken root while the valuation still prices C-MER Medical as if that shift barely matters.

Is C-MER Medical Holdings trading at a genuine disconnect from its fundamentals, or is the low P/E simply reflecting past flat earnings growth? See how the current price compares with our detailed valuation analysis for C-MER Medical Holdings

H1 2026 Earnings Summary

  • Revenue H1 2026 vs. H1 2025: HK$1,024.4m vs. HK$944.3m (around 8.5% higher)
  • Net Income H1 2026 vs. H1 2025: HK$50.0m vs. HK$49.9m (broadly stable)
  • Basic EPS H1 2026 vs. H1 2025: HK$0.0421 vs. HK$0.0411 (modest improvement)
  • Trailing 12-month Basic EPS to H1 2026 vs. to H1 2025: HK$0.0843 vs. a loss of HK$0.0950 (moved from loss to profit over the last year)

Prefer clear visuals over scrolling through paragraphs of earnings details and raw figures? See C-MER Medical Holdings' full financial picture with an at-a-glance view of its valuation in the interactive company report for C-MER Medical Holdings.

SEHK:3309 Trailing 12-Month Earnings & Revenue History as at Aug 2026
SEHK:3309 Trailing 12-Month Earnings & Revenue History as at Aug 2026

Where C-MER Medical’s Results Support Optimism

C-MER Medical Holdings is now reporting trailing 12 month basic EPS of HK$0.0843 after a loss in the prior comparable period, while net income in H1 2026 remains positive at HK$50.0m on HK$1,024.4m of revenue. That shift to consistent profitability fits the story of a specialist healthcare group that can support a broader platform. Revenue of just over HK$1.0b across diversified services also points to a business with meaningful scale rather than a single clinic concept.

Where The Bearish Concerns Still Hold Up

For a cautious view on C-MER Medical Holdings, the near flat net income of HK$50.0m versus HK$49.9m a year earlier is important. Profit is positive but not clearly accelerating. Basic EPS in H1 2026 is only modestly higher than H1 2025, which may raise questions about how quickly new segments contribute. Recent share price performance, down about 19% over 90 days, also suggests investors still want stronger evidence that diversification can lift earnings rather than just add complexity.

With C-MER Medical Holdings only recently moving into profit and long term growth still modest, liquidity and debt capacity matter more than ever. Verify how robust the balance sheet really is in the detailed financial health analysis of C-MER Medical Holdings stock.

Stay Ahead Of Your Next Move

If C-MER Medical Holdings looks interesting after its recent profitability and relatively low trailing P/E, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch for a better entry point. Once you own C-MER Medical Holdings or any other stock, use the Portfolio Command Center to cut through market noise and focus on the updates that matter for your holdings. For longer term conviction, lean on the Community to see what other investors are thinking and which factors they are watching. This way you can spot potential catalysts or risks earlier and stay one step ahead of the market.

Seeking Alternatives Beyond C-MER Medical

Fresh ideas do not wait. Stocks can move from quiet to breakout quickly, and momentum often flies once the crowd catches on, so review these under the radar ideas and act now.

  • Spot quieter momentum before it starts running by reviewing a curated mix of quality names in the 608 high quality undiscovered gems while they are still under the radar for now.
  • Strengthen income potential with companies that aim to keep cash flows steady by scanning the carefully filtered group of 409 dividend fortresses while yields still look appealing.
  • Focus on resilience while markets stay noisy by filtering for companies screened as 293 resilient stocks with low risk scores so you are not caught chasing stability after prices move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.